Optical coherence tomography biomarkers for myopic choroidal neovascularization treated with anti‐vascular endothelial growth factor
Open Access
- 14 March 2023
- journal article
- research article
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 39 (6) , 637-643
Abstract
In recent years, optical coherence tomography (OCT) biomarkers for specific retinal diseases have been found to be associated with treatment outcome and disease recurrence. The main purposes of this study were to identify OCT biomarkers for myopic choroidal neovascularization (mCNV) treated with intravitreal injection of anti‐vascular endothelial growth factor (anti‐VEGF). OCT features in 43 eyes of 39 patients with mCNV treated with anti‐VEGF with at least 1 year of follow‐up were retrospectively analyzed. Eyes with subretinal hyperreflective material (SHM) in baseline spectral‐domain OCT (SD‐OCT) had significantly more visual improvement than eyes without SHM at month 6 (p = 0.007) and had a trend of more visual improvement than eyes without SHM (p = 0.058) at month 12. Eyes with subretinal fluid (SRF) at baseline had significantly more central retinal thickness (CRT) decrease than patients without SRF at month 6 and 12 (p = 0.012 and 0.006 respectively). In univariate regression analysis, dome‐shaped macula (DSM), SRF in baseline OCT image and fuzzy border of mCNV when entering pro re nata (PRN) injection protocol tended to have higher risk of disease recurrence in 1 year (odds ratio: 14.86 (p = 0.003), 3.75 (p = 0.049) and 22.92 (p < 0.001) respectively). However, they were not significant in multivariate regression analysis. OCT biomarkers at baseline could provide prognostic information for mCNV management.Keywords
This publication has 23 references indexed in Scilit:
- International Photographic Classification and Grading System for Myopic MaculopathyAmerican Journal of Ophthalmology, 2015
- SUBRETINAL HYPERREFLECTIVE EXUDATION ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2014
- RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic MyopiaOphthalmology, 2014
- Epidemiology and Disease Burden of Pathologic Myopia and Myopic Choroidal Neovascularization: An Evidence-Based Systematic ReviewAmerican Journal of Ophthalmology, 2014
- Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularizationEye, 2012
- Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularizationEye, 2012
- Intravitreal Ranibizumab for Myopic Choroidal Neovascularization: Factors Predictive of Visual Outcome and Need for RetreatmentAmerican Journal of Ophthalmology, 2011
- Enhanced Depth Imaging Optical Coherence Tomography of the Sclera in Dome-Shaped MaculaAmerican Journal of Ophthalmology, 2011
- Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisationBritish Journal of Ophthalmology, 2009
- Dome-Shaped Macula in Eyes with Myopic Posterior StaphylomaAmerican Journal of Ophthalmology, 2008